MetasTx is developing a pipeline of novel cancer agents targeted at specific solid tumors based on advances in the delivery of IPA-3, a highly selective inhibitor of Group-1 P21 activated kinases (PAK).
An estimated 608,570 Americans died from cancer in 2021. The five-year survival rate of metastatic cancers, those that travel from the primary site to a distant site (also known as Stage 4 or 5), is approximately 30%.
Thi...
MetasTx is developing a pipeline of novel cancer agents targeted at specific solid tumors based on advances in the delivery of IPA-3, a highly selective inhibitor of Group-1 P21 activated kinases (PAK).
An estimated 608,570 Americans died from cancer in 2021. The five-year survival rate of metastatic cancers, those that travel from the primary site to a distant site (also known as Stage 4 or 5), is approximately 30%.
This area of research is ripe for advances. Unfortunately, current drug discovery in metastatic cancer has not resulted in therapies with significant increases in patient survival, specificity in drug delivery.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.